未经批准:2型单纯疱疹病毒(HSV-2)感染是一种全球流行的病毒,终身,性传播感染。这项研究描述了欧洲各种高危人群的HSV-2血清阳性率以及生殖器溃疡(GUD)和生殖器疱疹中HSV-2检测的比例。还审查了有关新生儿疱疹和HSV-2对HIV传播的贡献的数据。
未经评估:遵循Cochrane和PRISMA指南进行了系统审查,合成,并报告HSV-2相关发现。搜索在PubMed和Embase数据库中进行,直到2022年2月20日。包括任何报告结果测量数据的出版物。进行Meta分析和meta回归分析。
UNASSIGNED:确定了211份相关报告,包括12项总体发病率指标,总体294份(813份按年龄和性别等因素分层)血清阳性率测量,临床诊断的GUD中HSV-2检测的总体比例13(按性别分层15),在实验室确认的生殖器疱疹中,HSV-2检测的总体比例(183按年龄和性别等因素分层)为70。在一般人群中,合并平均血清阳性率为12.4%(95%CI:11.5-13.3%),27.8%(95%CI:17.5-39.4%)的男男性行为者,46.0%(95%CI:40.1-51.8%)在艾滋病毒感染者和艾滋病毒不和谐夫妇中,女性性工作者占63.2%(95%CI:55.5-70.6%)。大多数措施显示HSV-2血清阳性率的异质性。一般人群的合并平均血清阳性率随年龄增长而增加,男性比女性低0.65倍(95%CI:0.58-0.74)。血清阳性率每日历年下降1%。GUD和生殖器疱疹中HSV-2检测的平均比例为22.0%(95%CI:15.3-29.6%)和66.0%(95%CI:62.9-69.1%),分别。与女性相比,男性生殖器疱疹病例中的HSV-2检测高1.21倍(95%CI:1.10-1.32),每日历年下降1%。新生儿疱疹的发病率呈上升趋势。
UNASISIGNED:尽管血清阳性率在下降,欧洲很大一部分人口感染了HSV-2。HSV-2约占GUD病例的五分之一和生殖器疱疹病例的三分之二。研究结果支持需要投资于HSV-2疫苗开发,以及性健康和生殖健康服务。
UNASSIGNED:卡塔尔国家研究基金[NPRP9-040-3-008]和卡塔尔威尔康奈尔医学院生物医学研究计划的试点资金支持了这项研究。
UNASSIGNED: Herpes simplex virus type 2 (HSV-2) infection is a globally prevalent, life-long, sexually transmitted infection. This study characterized HSV-2 seroprevalence in Europe for various at-risk populations and proportions of HSV-2 detection in genital ulcer disease (GUD) and in genital herpes. Data on neonatal herpes and HSV-2\'s contribution to HIV transmission were also reviewed.
UNASSIGNED: Cochrane and PRISMA guidelines were followed to systematically review, synthesize, and report HSV-2 related findings. The search was conducted in PubMed and Embase databases up to February 20, 2022. Any publication reporting data on the outcome measures was included. Meta-analyses and meta-regressions were conducted.
UNASSIGNED: 211 relevant reports were identified, including 12 overall incidence measures, 294 overall (813 stratified by factors such as age and sex) seroprevalence measures, 13 overall (15 stratified by sex) proportions of HSV-2 detection in clinically diagnosed GUD, and 70 overall (183 stratified by factors such as age and sex) proportions of HSV-2 detection in laboratory-confirmed genital herpes. Pooled mean seroprevalence was 12.4% (95% CI: 11.5-13.3%) among general populations, 27.8% (95% CI: 17.5-39.4%) among men who have sex with men, 46.0% (95% CI: 40.1-51.8%) among people living with HIV and people in HIV discordant couples, and 63.2% (95% CI: 55.5-70.6%) among female sex workers. Most measures showed heterogeneity in HSV-2 seroprevalence. The pooled mean seroprevalence among general populations increased with age and was 0.65-fold (95% CI: 0.58-0.74) lower in men than women. Seroprevalence decreased by 1% per calendar year. Pooled mean proportions of HSV-2 detection in GUD and in genital herpes were 22.0% (95% CI: 15.3-29.6%) and 66.0% (95% CI: 62.9-69.1%), respectively. HSV-2 detection in genital herpes cases was 1.21-fold (95% CI: 1.10-1.32) higher in men compared to women and decreased by 1% per calendar year. Incidence of neonatal herpes indicated an increasing trend.
UNASSIGNED: Although seroprevalence is declining, a significant proportion of Europe\'s population is infected with HSV-2. HSV-2 accounts for approximately one-fifth of GUD cases and two-thirds of genital herpes cases. Findings support the need to invest in HSV-2 vaccine development, and sexual and reproductive health services.
UNASSIGNED: Qatar National Research Fund [NPRP 9-040-3-008] and pilot funding from the Biomedical Research Program at Weill Cornell Medicine in Qatar supported this study.